Jane Street Group LLC Has $59,000 Position in Paysign, Inc. (NASDAQ:PAYS)

Jane Street Group LLC cut its stake in shares of Paysign, Inc. (NASDAQ:PAYS) by 67.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,128 shares of the company’s stock after selling 32,800 shares during the quarter. Jane Street Group LLC’s holdings in Paysign were worth $59,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Algert Global LLC acquired a new position in shares of Paysign in the 2nd quarter valued at about $46,000. SG Americas Securities LLC bought a new stake in Paysign during the 3rd quarter worth approximately $43,000. The Manufacturers Life Insurance Company bought a new stake in Paysign during the 2nd quarter worth approximately $66,000. American Century Companies Inc. bought a new stake in Paysign during the 2nd quarter worth approximately $92,000. Finally, Bard Associates Inc. purchased a new position in shares of Paysign in the 3rd quarter worth approximately $103,000. 25.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Paysign

In other news, insider Matthew Louis Lanford sold 25,360 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $3.96, for a total transaction of $100,425.60. Following the transaction, the insider now directly owns 109,731 shares of the company’s stock, valued at approximately $434,534.76. This trade represents a 18.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark Newcomer sold 22,000 shares of the firm’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $3.75, for a total value of $82,500.00. Following the transaction, the chief executive officer now directly owns 9,414,886 shares in the company, valued at $35,305,822.50. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 943,447 shares of company stock valued at $3,050,294 over the last 90 days. 23.40% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PAYS. Lake Street Capital started coverage on Paysign in a research note on Friday, December 20th. They issued a “buy” rating and a $6.00 target price on the stock. Barrington Research restated an “outperform” rating and set a $7.00 target price on shares of Paysign in a research report on Monday, November 4th.

Paysign Stock Performance

Paysign stock opened at $3.07 on Thursday. The stock has a market cap of $164.39 million, a P/E ratio of 20.47 and a beta of 0.95. Paysign, Inc. has a fifty-two week low of $2.48 and a fifty-two week high of $5.59. The firm’s fifty day moving average price is $3.25 and its 200-day moving average price is $3.94.

Paysign (NASDAQ:PAYS) last released its earnings results on Tuesday, November 5th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.02. The business had revenue of $15.26 million for the quarter, compared to analysts’ expectations of $14.96 million. Paysign had a return on equity of 30.64% and a net margin of 14.28%. During the same quarter in the prior year, the firm earned $0.02 earnings per share. Sell-side analysts predict that Paysign, Inc. will post 0.21 earnings per share for the current year.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.